Our research indicated that targeting FOXM1 and motor adaptor BICD2 is an effective strategy to sensitize NVB, and DT-13 might be a practical candidate agent for the adjuvant chemotherapy of microtubule-interfering agents in NSCLC. This evidence concerns the gene BICD2 and non-small cell lung carcinoma.